Compare Blue Owl Capital Inc. Class A Common Stock (OWL) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Blue Owl Capital Inc. Class A Common Stock vs Tilray Brands Inc — how do they compare? Blue Owl Capital Inc. Class A Common Stock trades at $8.79 (market cap $6.35B), while Tilray Brands Inc trades at $3.11 (market cap $481.79M). The key difference: Blue Owl Capital Inc. Class A Common Stock is far larger — about 13.2× Tilray Brands Inc's market cap, and Blue Owl Capital Inc. Class A Common Stock pays a 9.8% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Blue Owl Capital Inc. Class A Common Stock for 0 Days and Tilray Brands Inc for 31 Days on average.
| OWL | TLRY | |
|---|---|---|
Market Cap | $6.35B | $481.79M |
Volume | 15,716,423 | 4,056,443 |
Sector | Financials | Health |
52-Week High | $17.17 | $16.80 |
52-Week Low | $8.23 | $3.14 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $10.53B | $635.71M |
Dividend Yield | 9.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Blue Owl Capital (OWL) trades at $9.29, down 0.54% on the day, with neutral technical indicators showing support at $9 and resistance at $10. The company reported mixed quarterly earnings, beating expectations in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Revenue growth remains steady at $2.9B in 2025, projected to $3.0B in 2026, though net margins are thin at 2.71%. Analyst sentiment is positive with 63% buy ratings and a $11.01 consensus target, but private credit fund redemptions and loan quality concerns present headwinds.
OWL offers value at a discount to analyst targets with strong institutional backing, but investors face risks from high P/E valuation (77.42), exposure to private credit volatility, and competitive pressures. The stock's 9.8% dividend yield and embedded fee growth from $31.1B in committed capital support upside, though execution on portfolio quality and redemption management will dictate near-term performance. Neutral outlook with cautious optimism pending Q3 earnings clarity.
Tilray Brands (TLRY) trades at $3.27, down 2.68% on the day and near 52-week lows, with bearish technical signals dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings misses and negative cash flow from operations highlight ongoing profitability challenges despite analyst consensus pointing to significant upside potential.
TLRY presents a high-risk opportunity with substantial analyst price target divergence. While valuation metrics appear attractive (P/S 0.4x, P/B 0.3x), persistent losses and cash burn require careful monitoring. The stock's fate hinges on cannabis reform progress and the company's ability to achieve sustainable profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Blue Owl Capital Inc. Class A Common Stock
Blue Owl Capital Inc. is an alternative asset manager that invests across credit, real assets, and GP strategic capital strategies, providing private capital solutions to businesses and to institutional and individual investors.
Read more on OWL →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
